Meloxicam tablet

DRUG6 trials

Sponsors

Boehringer Ingelheim

Conditions

Arthritis, RheumatoidHealthyOsteoarthritisSpondylitis, Ankylosing

Phase 1

Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers

CompletedNCT02183181

Boehringer IngelheimHealthy

Start: 2008-11-30Updated: 2014-07-08

Pharmacokinetics and Tolerability of Meloxicam Gel Compared to Meloxicam Tablets in Healthy Subjects

CompletedNCT02183077

Boehringer IngelheimHealthy

Start: 1998-09-30Updated: 2014-07-08

Pharmacokinetics and Tolerability of Meloxicam Injected Intramuscularly vs. Tablet in Healthy Subjects

CompletedNCT02183090

Boehringer IngelheimHealthy

Start: 1998-11-30Updated: 2014-07-08

Phase 3

A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis

CompletedNCT00239395

Boehringer IngelheimOsteoarthritis

Start: 2004-07-31End: 2004-12-31Target: 168Updated: 2013-11-01

A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis

CompletedNCT00239382

Boehringer IngelheimArthritis, Rheumatoid

Start: 2004-07-01End: 2004-12-31Target: 150Updated: 2018-08-03

Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis

CompletedNCT02183168

Boehringer IngelheimSpondylitis, Ankylosing

Start: 2001-07-01Updated: 2023-11-24